DekaBank Deutsche Girozentrale Purchases Shares of 50,000 Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

DekaBank Deutsche Girozentrale acquired a new stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $818,000.

A number of other hedge funds also recently made changes to their positions in DCPH. China Universal Asset Management Co. Ltd. grew its stake in shares of Deciphera Pharmaceuticals by 96.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock valued at $26,000 after acquiring an additional 997 shares during the period. Lazard Asset Management LLC bought a new position in shares of Deciphera Pharmaceuticals during the 1st quarter valued at approximately $57,000. Compass Wealth Management LLC bought a new position in shares of Deciphera Pharmaceuticals during the 4th quarter valued at approximately $70,000. Advisor Group Holdings Inc. lifted its holdings in Deciphera Pharmaceuticals by 78.0% in the 4th quarter. Advisor Group Holdings Inc. now owns 4,331 shares of the company’s stock worth $71,000 after purchasing an additional 1,898 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Deciphera Pharmaceuticals by 144.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,817 shares of the company’s stock worth $96,000 after purchasing an additional 4,024 shares in the last quarter. 70.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Stifel Nicolaus boosted their price target on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. JPMorgan Chase & Co. boosted their price target on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Deciphera Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Deciphera Pharmaceuticals Trading Down 1.0 %

NASDAQ DCPH opened at $14.90 on Tuesday. The stock has a market cap of $1.20 billion, a PE ratio of -6.51 and a beta of 0.39. Deciphera Pharmaceuticals, Inc. has a 12 month low of $9.90 and a 12 month high of $17.73. The stock’s 50 day moving average is $15.68 and its 200 day moving average is $14.19.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. The business had revenue of $48.30 million for the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company’s revenue for the quarter was up 32.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.60) EPS. On average, analysts forecast that Deciphera Pharmaceuticals, Inc. will post -2.16 EPS for the current fiscal year.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.